超声辅助导管定向纤溶治疗急性肺栓塞
该多国适应性设计试验纳入中危急性肺栓塞患者(右室/左室舒张末内径比≥1.0且肌钙蛋白升高,并至少两项心肺窘迫指标:收缩压≤110 mm Hg、心率≥100次/分或呼吸频率>20次/分),随机接受超声辅助导管定向阿替普酶纤溶联合抗凝(干预组273例)或单用抗凝(对照组271例)。主要终点为7天内肺栓塞相关死亡、心肺失代偿或崩溃、或症状性肺栓塞复发的复合终点,干预组发生11例(4.0%)vs 对照组28例(10.3%)(RR 0.39,95%CI 0.20-0.77,P=0.005),效应主要由心肺失代偿或崩溃风险降低驱动。7天内大出血干预组11例(4.1%)vs 对照组6例(2.2%)(P=0.32),30天内分别为11例(4.1%)vs 8例(3.0%)(P=0.64),无颅内出血。
要点
- 中危肺栓塞(右室/左室比≥1.0、肌钙蛋白升高、至少两项心肺窘迫指标)患者中,超声辅助导管定向阿替普酶纤溶联合抗凝较单用抗凝降低7天主要复合终点(4.0% vs 10.3%,RR 0.39,95%CI 0.20-0.77)。
- 主要终点效应主要由心肺失代偿或崩溃风险降低驱动。
- 7天内大出血干预组4.1% vs 对照组2.2%(P=0.32),30天内4.1% vs 3.0%(P=0.64),无颅内出血。
- 30天内其他严重不良事件两组间无实质差异。
- 研究为多国适应性设计试验,结局判定设盲,由Boston Scientific资助(HI-PEITHO,NCT04790370)。
适用人群与场景
- 中危急性肺栓塞患者,符合右室舒张末内径与左室舒张末内径比值≥1.0且肌钙蛋白升高。
- 并至少具备两项心肺窘迫指标:收缩压≤110 mm Hg、心率≥100次/分、呼吸频率>20次/分。
诊断标准与关键阈值
- 中危肺栓塞纳入标准:右室/左室舒张末内径比≥1.0、肌钙蛋白升高、至少两项心肺窘迫指标(收缩压≤110 mm Hg、心率≥100次/分、呼吸频率>20次/分)。
处置流程与药物剂量
- 干预组:超声辅助导管定向纤溶使用阿替普酶,联合抗凝,按预设治疗方案执行。
- 对照组:单用抗凝,按预设治疗方案执行。
红旗征与不能漏的情况
- 心肺失代偿或崩溃为研究主要终点组成部分,干预组风险较对照组降低。
研究设计与关键结果
- 多国适应性设计试验,意向性治疗人群544例:干预组273例,对照组271例;平均年龄58.2±13.5岁,女性42.6%。
- 7天内主要复合终点(肺栓塞相关死亡、心肺失代偿或崩溃、症状性肺栓塞复发):干预组11例(4.0%,95%CI 2.3-7.1)vs 对照组28例(10.3%,95%CI 7.2-14.5),RR 0.39(95%CI 0.20-0.77),P=0.005。
- 效应主要由干预组心肺失代偿或崩溃风险降低驱动。
- 7天内大出血:干预组11例(4.1%)vs 对照组6例(2.2%),P=0.32;30天内大出血:干预组11例(4.1%)vs 对照组8例(3.0%),P=0.64。
- 30天内其他严重不良事件两组间无实质差异;无颅内出血发生。
证据类型、等级与局限
- 研究类型:多国适应性设计试验,结局判定设盲。
- 资助:Boston Scientific;HI-PEITHO,ClinicalTrials.gov NCT04790370。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于中危急性肺栓塞且符合纳入标准(右室/左室比≥1.0、肌钙蛋白升高、至少两项心肺窘迫指标)的患者,超声辅助导管定向阿替普酶纤溶联合抗凝较单用抗凝降低7天内肺栓塞相关死亡、心肺失代偿或崩溃、症状性复发复合终点风险。
- 7天内大出血干预组4.1% vs 对照组2.2%(P=0.32),30天内4.1% vs 3.0%(P=0.64),无颅内出血,两组其他严重不良事件无实质差异。
指南或共识出处
- HI-PEITHO试验,ClinicalTrials.gov NCT04790370。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain.
METHODS: We conducted a multinational, adaptive-design trial with blinded outcome adjudication. Patients with intermediate-risk pulmonary embolism (with a ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter of ≥1.0 and an elevated troponin level) were eligible if they had at least two indicators of cardiorespiratory distress (systolic blood pressure of ≤110 mm Hg, a heart rate of ≥100 beats per minute, or a respiratory rate of >20 breaths per minute). Patients were randomly assigned to undergo ultrasound-facilitated, catheter-directed fibrinolysis with alteplase plus anticoagulation (the intervention group) or anticoagulation alone (the control group) according to prespecified treatment protocols. The primary outcome was a composite of pulmonary embolism-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days.
RESULTS: The intention-to-treat population comprised 544 patients: 273 in the intervention group and 271 in the control group. The mean (±SD) age was 58.2±13.5 years, and 42.6% of the patients were women. A primary-outcome event occurred in 11 patients (4.0%; 95% confidence interval [CI], 2.3 to 7.1) in the intervention group and 28 (10.3%; 95% CI, 7.2 to 14.5) in the control group (relative risk, 0.39; 95% CI, 0.20 to 0.77; P = 0.005). The effect was driven primarily by a lower risk of cardiorespiratory decompensation or collapse in the intervention group. Major bleeding occurred within 7 days after randomization in 11 patients (4.1%) in the intervention group and 6 (2.2%) in the control group (P = 0.32); major bleeding occurred within 30 days in 11 patients (4.1%) and 8 patients (3.0%), respectively (P = 0.64). No substantial between-group differences in the incidence of other serious adverse events were observed up to 30 days after randomization; no intracranial hemorrhage occurred.
CONCLUSIONS: In patients with acute, intermediate-risk pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis plus anticoagulation led to a lower risk of the composite of pulmonary embolism-related death, cardiopulmonary decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days than anticoagulation alone. (Funded by Boston Scientific; HI-PEITHO ClinicalTrials.gov number, NCT04790370.).
参考来源
- Rosenfield K, Klok FA, Piazza G, et al. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. N Engl J Med. 2026. PMID: 41910345. doi:10.1056/NEJMoa2516567
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。